Allogene Therapeutics has received FDA approval to investigate a new drug, ALLO-715, an experimental BCMA AlloCAR T therapy to treat patients with relapsed or refractory multiple myeloma. Enrollment of the first volunteers in this study is expected to begin in Q1 2021.